Using Coverage and Claims Data Provides Pharma a View of Payer and Prescriber Behavior
Insufficient return on investment due to an underperforming launch is a thought that makes any pharma manufacturer shudder. Considering that about half of all products launched over the last 15 years have underperformed pre-launch consensus forecasts by more than 20%, companies must proactively plan their near- and long-term strategies to ensure financial losses remain a […]
How Real-World Evidence is Impacting Regulatory Decision-Making: 12 Recent Approvals Based on RWE
Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE.
Clinical Pathways: What Are They, and How Do They Affect Access?
Pharma manufacturers working within oncology, and a few other select fields, face a unique challenge when bringing their therapies to market: clinical pathways. According to MMIT Pulse Analytics data, roughly 62% of U.S. oncologists are currently exposed to a clinical pathway. And of those using pathways, adherence is high, with 80% sticking to the recommended […]
Improving Market Access: Are You Making the Most of Real-World Data?
As drug and therapy innovation becomes more specialized and costs continue to rise, improving market access becomes more complicated. As the landscape evolves, pharma manufacturers must strategize accordingly to ensure a successful launch. Navigating the changing market access landscape is a common struggle for pharma manufacturers: One study found that 50% of all pharma manufacturers […]
What the Changing Definition of Patient Access Means for Pharma Manufacturers
The shift away from blockbuster drugs has led the pharmaceutical industry toward more specialized drugs and therapeutic areas for rare diseases, oncology and gene therapy. This wave of specialized, niche therapies has not only necessitated a more in-depth approach to commercialization but also led to increasingly complex payer policies that are changing the definition of […]
Breaking Down the Top Three Barriers to Patient Access
Payers drive an increasingly large portion of the decision-making surrounding patient access. They determine how a drug is placed on formulary, what restrictions should exist, how and when patients qualify, etc., before patients can access a life-saving therapy or treatment. This means that pharma manufacturers who want their products widely used by patients must take […]
Market Access Speed is the Next Critical Differentiator for Pharma Manufacturers
With the cost of healthcare and drug discovery continuing to rise and value-based contracting gaining traction, demonstrating a product’s economic value compared to existing competitor products is more important than ever. Drugs today need to be reimbursable, not just approvable, writes MMIT’s Dinesh Kabaleeswaran in an article for PharmExec.
